Teva was hoping to level the convenience playing field in severe asthma with a subcutaneous version of Cinqair. But those plans have hit a snag.
Sanofi finally scored a deal. It plans to shell out $11.6 billion for Bioverativ, the hemophilia-focused drugmaker spun off by Biogen just last year.
Teva’s far-reaching cost cuts are hitting close to home—not just in Israel, but at its North American headquarters, too.
PTC is facing questions about an issue that has dogged the company since it bought DMD drug Emflaza from Marathon last March: the drug’s rising price.
Earlier this month, reports said Acorda could be scouting buyers. And now, rumors are swirling as to who those potential bidders might be.
Sanofi's already-hit U.S. diabetes and cardiovascular sales team is set for another round of layoffs.
AbbVie is investing $139 million in a sterile manufacturing expansion and adding 100 jobs at its plant in Sligo to produce future cancer drugs.
J&J's diabetes unit attracts Chinese buyers, Novartis and Biocon form a biosimilar deal, plus Keytruda-Lenvima combo gets a breakthrough tag.
Sick of dealing with generic drug shortages and price increases, five large U.S. health systems are forming their own drugmaker.
Analysts previously signaled that market share for Allergan’s Botox should be safe after competitors show up. But a new survey indicates otherwise.